VolitionRX Limited (VNRX)
| Market Cap | 162.38M |
| Revenue (ttm) | 38,419 |
| Net Income (ttm) | -20.62M |
| Shares Out | 52.89M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $3.01 |
| Previous Close | $3.16 |
| Change ($) | -0.15 |
| Change (%) | -4.75% |
| Day's Open | 3.17 |
| Day's Range | 2.96 - 3.23 |
| Day's Volume | 247,874 |
| 52-Week Range | 2.78 - 6.67 |
Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfolio ...
AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss ...
AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial fo...
AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to disc...
AUSTIN, Texas, March 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Cameron Reynolds, and its Executive Vice President, I...
Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of cancer diag...
VolitionRx began commercial sales of a blood test for pet cancer. There is no other product available on the market for testing cancer in dogs despite cancer being the leading cause of death for dogs ov...
DOUGLAS, Isle of Man--(BUSINESS WIRE)--Cotterford Co. Ltd. (“Cotterford”) the beneficial owner of approximately 26% of the outstanding shares of VolitionRX Limited (“Volition”) (AMEX: VNRX), today sent ...
VolitionRx (VNRX) Investor Presentation - Slideshow
VolitionRx Limited's (VNRX) CEO Cameron Reynolds on Q3 2019 Results - Earnings Call Transcript
These healthcare stocks are all worth a "buy" now. The healthcare sector will keep chugging along despite market volatility.
VolitionRX Limited (VNRX) CEO Cameron Reynolds on Q2 2019 Results - Earnings Call Transcript
VolitionRX Ltd. (VNRX) CEO Cameron Reynolds on Q4 2018 Results - Earnings Call Transcript
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
| Industry Diagnostics & Research | |
| Stock Exchange NYSEAMERICAN | Ticker Symbol VNRX |
Financial Performance
In 2020, VolitionRX's revenue was $13,433, a decrease of -21.43% compared to the previous year's $17,096. Losses were -$20.35 million, 26.4% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for VolitionRX stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 165.78% from the latest price.